SABCS 2023 Preview
An Expert’s Guide to SABCS 2023: A Preview of the Top Abstracts

Released: December 04, 2023

Activity

Progress
1
Course Completed

During the 2023 San Antonio Breast Cancer Symposium (SABCS), exciting and important results from many studies will be reported. In this commentary, breast cancer experts Sara A. Hurvitz, MD, and Joyce O’Shaughnessy, MD, highlight the abstracts they are most looking forward to seeing presented at the meeting.

We will cover these abstracts in more detail as part of the Clinical Care Options (CCO) Independent Conference Coverage of SABCS 2023. As the meeting unfolds, remember to check the CCO website for downloadable slidesets, including the data from these highlighted studies. After the conference, review the CME/CNE/CPE/AAPA-certified expert analysis text module with perspectives and clinical implications of these new data.

Top Picks
The following abstracts are highly anticipated by our experts:

  • monarchE: An analysis of the genomic and transcriptomic profiles of primary tumors (Abstract GS03-06) and a pilot study on detecting ctDNA (Abstract PS06-01) in patients with hormone receptor (HR)–positive/HER2-negative, high-risk early breast cancer (EBC) from this phase III trial of adjuvant abemaciclib.
  • KEYNOTE-756: A phase III study of patients with estrogen receptor (ER)–positive/HER2-negative, high-risk EBC treated with pembrolizumab or placebo added to neoadjuvant chemotherapy followed by adjuvant pembrolizumab or placebo added to endocrine therapy (Abstract GS01-02).
  • An exploratory biomarker analysis of the phase III CheckMate 7FL trial comparing the addition of nivolumab vs placebo to neoadjuvant chemotherapy and adjuvant endocrine therapy in patients with ER-positive/HER2-negative, high-risk EBC (Abstract GS01-01).
  • First presentation of data from HER2CLIMB-02, a large, randomized, double-blind phase III trial of tucatinib plus trastuzumab emtansine vs placebo plus trastuzumab emtansine in patients with HER2-positive advanced breast cancer (ABC) previously treated with a taxane and trastuzumab (Abstract GS01-10).
  • TROPION-Breast01: Efficacy, safety, and biomarker data from the phase III trial comparing datopotamab deruxtecan vs chemotherapy in patients with HR-positive/HER2-negative ABC (Abstract GS02-01).

Additional Abstracts of Interest

  • Primary outcomes from the phase III NRG Oncology/NSABP B-51/RTOG 1304 trial assessing comprehensive radiation therapy vs standard of care following mastectomy or breast-conserving surgery in patients with EBC and pathologically positive axillary nodes who are ypN0 after neoadjuvant chemotherapy (Abstract GS02-07).
  • NATALEE: The final analysis of invasive disease–free survival with adjuvant ribociclib plus a nonsteroidal aromatase inhibitor vs a nonsteroidal aromatase inhibitor alone in patients with HR-positive/HER2-negative EBC from the phase III study (Abstract GS03-03).
  • A late-breaking abstract on the randomized, noncomparative phase II “Neo-N” trial (BCT1902/IBCSG 61-20 Neo-N) evaluating pathologic complete response rates in patients with early triple-negative breast cancer (TNBC) who received neoadjuvant therapy with concurrent nivolumab and chemotherapy with or without a lead-in of single-agent nivolumab (Abstract LBO1-03).
  • Negative but informative data from an interim analysis of the phase III ALEXANDRA/IMpassion030 trial evaluating the addition of atezolizumab to adjuvant anthracycline/taxane-based chemotherapy in patients with stage II/III TNBC (Abstract GS1-03).
  • Outcomes by age in the phase III TROPiCS-02 trial comparing sacituzumab govitecan vs treatment of physician’s choice in patients with HR-positive/HER2-negative metastatic breast cancer (Abstract PO5-21-09).
  • An analysis of the cohort with confirmed leptomeningeal carcinomatosis from the DEBBRAH trial assessing trastuzumab deruxtecan in patients with HER2-positive or HER2-low ABC (Abstract PS11-05).
  • First presentation of data from KEYLYNK-009, a randomized, open-label phase II trial comparing the efficacy of pembrolizumab plus olaparib vs pembrolizumab plus chemotherapy after induction treatment with pembrolizumab plus chemotherapy in patients with advanced TNBC (Abstract GS01-05).

Remember to Check the CCO Website Often During and After SABCS 2023!
Downloadable slideset summaries of these key studies will be available on the CCO website as the data are released. After SABCS 2023, comprehensive analyses by our expert faculty will explore the clinical implications of the data in a CME/CNE/CPE/AAPA-certified text-based module.

Poll

1.

Which of the following studies are you most looking forward to seeing presented at SABCS 2023?

Submit